<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647320</url>
  </required_header>
  <id_info>
    <org_study_id>DS8500-A-U202</org_study_id>
    <nct_id>NCT02647320</nct_id>
  </id_info>
  <brief_title>12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this Phase 2, 12-week study, is that DS-8500a will improve glycemic control
      relative to placebo, based on changes in HbA1c, with acceptable safety and tolerability, in
      patients with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the three-month average glucose concentration in the blood. Target HbA1c for Type 2 diabetics was less than 7% at the time of this trial. Negative scores show improvement from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol (TC) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>LDL-C is known as the &quot;bad&quot; cholesterol, so a lower score (negative change) means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HDL-C at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>HDL-C is known as the &quot;good&quot; cholesterol, so a higher score (positive change) means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Non-HDL-C at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Non-HDL-C is the measure of &quot;bad&quot; cholesterol in the blood, including triglycerides and LDL-C, so a negative change means improvement. The equation for Non-HDL-C = LDL-C + (triglycerides/5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Triglycerides are a type of fat found in the blood. The body uses them for energy. Some triglycerides are needed for good health. But high triglycerides might raise the risk of heart disease. Since Type 2 diabetics tend to have high triglycerides, a negative change means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Area-Under-the Curve 0-3 Hours (AUC0-3h) of Plasma Glucose (PG) in Response to the Mixed Meal Tolerance Test (MMTT) at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The MMTT requires a participant to drink a &quot;mixed meal,&quot; such as Boost or Ensure, that contains protein, carbohydrates, and fat. The goal of the test is to find out how much insulin the pancreas makes in response to food by measuring the level of glucose in the blood. The lower the level of glucose in the blood during the first three hours after the test (AUC0-3h), the more insulin the body has made in response to the test. This would mean a negative change shows improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in AUC0-3h of PG in Response to the MMTT at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The MMTT requires a participant to drink a &quot;mixed meal,&quot; such as Boost or Ensure, that contains protein, carbohydrates, and fat. The goal of the test is to find out how much insulin the pancreas makes in response to food by measuring the level of glucose in the blood. The lower the level of glucose in the blood during the first three hours after the test (AUC0-3h), the more insulin the body has made in response to the test. This would mean a negative change shows improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Maximum Concentration (Cmax) of PG in Response to MMTT at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Cmax measures the highest amount of glucose in the blood, so a negative change means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cmax of PG in Response to MMTT at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Cmax measures the highest amount of glucose in the blood, so a negative change means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With HbA1c Less Than 7.0% at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>HbA1C less than 7% is the success goal for many Type 2 diabetics.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DS-8500a 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-8500a 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-8500a 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three placebo tablets and one placebo capsule in a once-daily oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100 mg</intervention_name>
    <description>Two sitagliptin 50 mg tablets, over-encapsulated to provide a once-daily dose of 100 mg, for oral administration</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-8500a 25mg</intervention_name>
    <description>DS-8500a 25mg tablet for oral administration</description>
    <arm_group_label>DS-8500a 25mg</arm_group_label>
    <arm_group_label>DS-8500a 50 mg</arm_group_label>
    <arm_group_label>DS-8500a 75 mg</arm_group_label>
    <other_name>Investigational product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Placebo matching DS-8500a tablet for oral administration</description>
    <arm_group_label>DS-8500a 25mg</arm_group_label>
    <arm_group_label>DS-8500a 50 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>Placebo matching sitagliptin over-capsule for oral administration</description>
    <arm_group_label>DS-8500a 25mg</arm_group_label>
    <arm_group_label>DS-8500a 50 mg</arm_group_label>
    <arm_group_label>DS-8500a 75 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent and adhere to the study visit schedule and
             treatment

          -  Diagnosed with Type 2 diabetes mellitus as defined in the American Diabetes
             Association Standards of Medical Care in Diabetes 2015

          -  Male or female ≥ 18 and ≤ 70 years of age

          -  Screening fasting C-peptide &gt; 0.5 ng/mL

          -  Women of child bearing potential (WOCBP) must be willing to use double-barrier
             contraception for the entire study

          -  WOCBP must have a negative pregnancy test (human chorionic gonadotropin, beta subunit
             [βhCG]) before entering the Lead-in Period

          -  Body mass index ≥ 25 kg/m2 and ≤ 45 kg/m2 at the Screening Visit

          -  On stable (≥ 8 weeks) metformin monotherapy ≥ 1000 mg/day

          -  Screening HbA1c ≥ 7.0% and ≤ 10%

          -  Taking ≥ 80% and ≤ 120% of both dispensed DS-8500a placebo tablets and sitagliptin
             placebo capsules during the Lead-in Period

        Exclusion Criteria:

          -  History of type 1 diabetes and/or history of ketoacidosis

          -  History of insulin use for &gt; 2 weeks within 2 months prior to the Screening Visit

          -  Two or more readings of fasting Self-monitoring of Blood Glucose (SMBG) &gt; 240 mg/dL or
             worsening symptoms of hyperglycemia with one SMBG level of &gt; 240 mg/dL during the
             second week of Lead-in Period, confirmed by laboratory measurement

          -  Screening hemoglobin &lt;12 g/dL for males and &lt;11 g/dL for females

          -  Blood donation within 2 months prior to the Screening Visit or plans to donate blood
             or blood products during the study

          -  Subjects after bariatric surgery or any gastric bypass

          -  Screening thyroid stimulating hormone (TSH) levels not within normal range (based on
             reference laboratory values )

          -  Screening Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) &gt; 2.0 x
             upper limit of normal (ULN), and/or total bilirubin &gt; 1.5 x ULN. If a subject has
             total bilirubin &gt; 1.5 ULN, unconjugated and conjugated bilirubin fractions should be
             analyzed and only subjects documented to have Gilbert's syndrome may be enrolled

          -  Screening Serum creatinine ≥ 1.5 mg/dL for males and ≥ 1.4 mg/dL for females, or
             creatinine clearance (CrCl) &lt; 50 mL/min for both males and females

          -  Screening Creatine kinase (CK) &gt; 3.0 × ULN

          -  History of unstable angina, myocardial infarction, cerebrovascular accident, transient
             ischemic attack, peripheral arterial event or any revascularization procedure during
             the 6 months prior to the Screening Visit or planned vascular procedures or surgery
             during study period

          -  History of congestive heart failure (CHF)

          -  Exclusionary concomitant medications:

             a. Eight weeks prior to screening and throughout the duration of the study:

          -  Any diabetes medication other than metformin; any prescription or over the counter
             medication for weight-loss.

          -  Systemic corticosteroids (including nasal and inhaled), with the exception of use of
             topical and ophthalmic corticosteroids.

          -  Rosuvastatin &gt; 20 mg daily. b. During treatment periods, additional medications will
             be prohibited based on potential drug-drug interaction (DDI) (see Section 5.6)

          -  Subjects with anticipated interruption in metformin or study drug use during the
             course of the clinical trial (e.g., due to an imaging procedure involving iodinated
             contrast media)

          -  Subjects in whom treatment with sitagliptin 100 mg is contraindicated ( e.g., known
             hypersensitivity or intolerance to sitagliptin) or may not be medically advisable
             (e.g., history of pancreatitis)

          -  Abuse of or dependence on prescription medications, illicit drugs, or alcohol within
             the last 1 year

          -  Any history of a malignancy other than basal cell carcinoma within the past 5 years

          -  Pregnancy or breast-feeding, or intent to become pregnant during the study period

          -  Known (or evidence of) infection with human immunodeficiency virus

          -  Any condition, laboratory abnormality, or concomitant therapy which, in the opinion of
             the Investigator, might pose a risk to the subject or make participation not in the
             subject's best interest

          -  Subject is currently enrolled in or has not yet completed at least 30 days since
             ending another investigational device or drug study or is receiving other
             investigational agents

          -  A direct or familial relationship with the Sponsor, Investigator, or site personnel
             affiliated with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Litchfield Park</city>
        <state>Arizona</state>
        <zip>85340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chino</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gold River</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Indiana</state>
        <zip>46131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenfield</city>
        <state>Indiana</state>
        <zip>46140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 4A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5GB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4N 2W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <results_first_submitted>January 26, 2018</results_first_submitted>
  <results_first_submitted_qc>March 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2018</results_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>interventional</keyword>
  <keyword>double blind</keyword>
  <keyword>phase 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 654 subjects were recruited at multiple sites in the United States and Canada.</recruitment_details>
      <pre_assignment_details>A total of 654 subjects were screened and 297 subjects passed the run-in screening period and were randomized. One subject failed screening but was randomized in error.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DS-8500a 25mg</title>
          <description>One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose</description>
        </group>
        <group group_id="P2">
          <title>DS-8500a 50 mg</title>
          <description>Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose</description>
        </group>
        <group group_id="P3">
          <title>DS-8500a 75 mg</title>
          <description>Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose</description>
        </group>
        <group group_id="P4">
          <title>Sitagliptin 100 mg</title>
          <description>Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Three placebo tablets and one placebo capsule in a once-daily oral dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Inadvertently Randomized</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent-to-Treat Set (mITT)</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="62"/>
                <participants group_id="P5" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Persistent hyperglycemia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not provided</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Develop anemia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disposition Missing Due to Fire at Site</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants randomized</population>
      <group_list>
        <group group_id="B1">
          <title>DS-8500a 25mg</title>
          <description>One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose</description>
        </group>
        <group group_id="B2">
          <title>DS-8500a 50 mg</title>
          <description>Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose</description>
        </group>
        <group group_id="B3">
          <title>DS-8500a 75 mg</title>
          <description>Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose</description>
        </group>
        <group group_id="B4">
          <title>Sitagliptin 100 mg</title>
          <description>Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Three placebo tablets and one placebo capsule in a once-daily oral dose</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="68"/>
            <count group_id="B5" value="69"/>
            <count group_id="B6" value="298"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="69"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="9.30"/>
                    <measurement group_id="B2" value="57.0" spread="8.95"/>
                    <measurement group_id="B3" value="57.0" spread="9.41"/>
                    <measurement group_id="B4" value="57.4" spread="7.77"/>
                    <measurement group_id="B5" value="55.6" spread="7.72"/>
                    <measurement group_id="B6" value="56.7" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="69"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="69"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="69"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="46"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="69"/>
                    <count group_id="B4" value="68"/>
                    <count group_id="B5" value="69"/>
                    <count group_id="B6" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>1. Glycated Hemoglobin</title>
          <description>Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the three-month average glucose concentration in the blood. Target HbA1c for Type 2 diabetics was less than 7% at the time of this trial. Negative scores show improvement from baseline.</description>
          <population>Modified Intent to Treat (mITT) Set, defined as all participants in the Safety Set who have a baseline measurement and at least 1 post-baseline measurement. mITT was used for analysis because one of the sites had a fire so 16 participants who were included in the baseline population were not included in analyses.</population>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="61"/>
                    <count group_id="B4" value="62"/>
                    <count group_id="B5" value="62"/>
                    <count group_id="B6" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.94" spread="0.939"/>
                    <measurement group_id="B2" value="8.09" spread="0.910"/>
                    <measurement group_id="B3" value="7.99" spread="0.900"/>
                    <measurement group_id="B4" value="7.78" spread="0.790"/>
                    <measurement group_id="B5" value="7.92" spread="0.699"/>
                    <measurement group_id="B6" value="7.93" spread="0.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2. Total Cholesterol</title>
          <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
          <population>Modified Intent to Treat (mITT) Set, defined as all participants in the Safety Set who have a baseline measurement and at least 1 post-baseline measurement. mITT was used for analysis because one of the sites had a fire so 16 participants who were included in the baseline population were not included in analyses.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="61"/>
                    <count group_id="B4" value="62"/>
                    <count group_id="B5" value="62"/>
                    <count group_id="B6" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177.1" spread="36.72"/>
                    <measurement group_id="B2" value="180.3" spread="32.21"/>
                    <measurement group_id="B3" value="178.0" spread="37.38"/>
                    <measurement group_id="B4" value="172.6" spread="55.25"/>
                    <measurement group_id="B5" value="182.8" spread="43.11"/>
                    <measurement group_id="B6" value="178.1" spread="41.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>3. Low Density Lipoprotein-C</title>
          <description>LDL-C is known as the &quot;bad&quot; cholesterol, so a lower score (negative change) means improvement.</description>
          <population>Modified Intent to Treat (mITT) Set, defined as all participants in the Safety Set who have a baseline measurement and at least 1 post-baseline measurement. mITT was used for analysis because one of the sites had a fire so 16 participants who were included in the baseline population were not included in analyses.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="61"/>
                    <count group_id="B4" value="62"/>
                    <count group_id="B5" value="62"/>
                    <count group_id="B6" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.6" spread="33.58"/>
                    <measurement group_id="B2" value="96.9" spread="30.53"/>
                    <measurement group_id="B3" value="96.6" spread="32.84"/>
                    <measurement group_id="B4" value="95.1" spread="37.93"/>
                    <measurement group_id="B5" value="99.8" spread="37.14"/>
                    <measurement group_id="B6" value="97.0" spread="34.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>4. High Density Lipoprotein-C</title>
          <description>HDL-C is known as the &quot;good&quot; cholesterol, so a higher score (positive change) means improvement.</description>
          <population>Modified Intent to Treat (mITT) Set, defined as all participants in the Safety Set who have a baseline measurement and at least 1 post-baseline measurement. mITT was used for analysis because one of the sites had a fire so 16 participants who were included in the baseline population were not included in analyses.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="61"/>
                    <count group_id="B4" value="62"/>
                    <count group_id="B5" value="62"/>
                    <count group_id="B6" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" spread="12.80"/>
                    <measurement group_id="B2" value="49.3" spread="13.20"/>
                    <measurement group_id="B3" value="46.4" spread="11.77"/>
                    <measurement group_id="B4" value="44.3" spread="12.17"/>
                    <measurement group_id="B5" value="46.7" spread="10.93"/>
                    <measurement group_id="B6" value="46.87" spread="12.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>5. Non-High Density Lipoprotein-C</title>
          <description>Non-HDL-C is the measure of &quot;bad&quot; cholesterol in the blood, including triglycerides and LDL-C, so a negative change means improvement. The equation for Non-HDL-C = LDL-C + (triglycerides/5).</description>
          <population>Modified Intent to Treat (mITT) Set, defined as all participants in the Safety Set who have a baseline measurement and at least 1 post-baseline measurement. mITT was used for analysis because one of the sites had a fire so 16 participants who were included in the baseline population were not included in analyses.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="61"/>
                    <count group_id="B4" value="62"/>
                    <count group_id="B5" value="62"/>
                    <count group_id="B6" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127.6" spread="38.13"/>
                    <measurement group_id="B2" value="131.0" spread="32.54"/>
                    <measurement group_id="B3" value="131.6" spread="35.93"/>
                    <measurement group_id="B4" value="128.4" spread="44.46"/>
                    <measurement group_id="B5" value="136.1" spread="40.69"/>
                    <measurement group_id="B6" value="131.21" spread="38.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6. Triglycerides</title>
          <description>Triglycerides are a type of fat found in the blood. The body uses them for energy. Some triglycerides are needed for good health. But high triglycerides might raise the risk of heart disease. Since Type 2 diabetics tend to have high triglycerides, a negative change means improvement.</description>
          <population>Modified Intent to Treat (mITT) Set, defined as all participants in the Safety Set who have a baseline measurement and at least 1 post-baseline measurement. mITT was used for analysis because one of the sites had a fire so 16 participants who were included in the baseline population were not included in analyses.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="61"/>
                    <count group_id="B4" value="62"/>
                    <count group_id="B5" value="62"/>
                    <count group_id="B6" value="263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.3" spread="114.5"/>
                    <measurement group_id="B2" value="174.9" spread="95.55"/>
                    <measurement group_id="B3" value="179.6" spread="83.39"/>
                    <measurement group_id="B4" value="169.8" spread="84.90"/>
                    <measurement group_id="B5" value="184.2" spread="91.02"/>
                    <measurement group_id="B6" value="175.5" spread="94.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12</title>
        <description>Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the three-month average glucose concentration in the blood. Target HbA1c for Type 2 diabetics was less than 7% at the time of this trial. Negative scores show improvement from baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Modified Intent to Treat (mITT) Set, defined as all participants in the Safety Set who have a baseline measurement and at least 1 post-baseline measurement. mITT was used for analysis because one of the sites had a fire so 16 participants who were included in the baseline population were not included in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12</title>
          <description>Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the three-month average glucose concentration in the blood. Target HbA1c for Type 2 diabetics was less than 7% at the time of this trial. Negative scores show improvement from baseline.</description>
          <population>Modified Intent to Treat (mITT) Set, defined as all participants in the Safety Set who have a baseline measurement and at least 1 post-baseline measurement. mITT was used for analysis because one of the sites had a fire so 16 participants who were included in the baseline population were not included in analyses.</population>
          <units>percent of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="1.019"/>
                    <measurement group_id="O2" value="-0.16" spread="0.798"/>
                    <measurement group_id="O3" value="-0.35" spread="0.791"/>
                    <measurement group_id="O4" value="-0.66" spread="0.623"/>
                    <measurement group_id="O5" value="-0.23" spread="0.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.755</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.157</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.211</ci_lower_limit>
            <ci_upper_limit>0.309</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.512</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.161</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.160</ci_lower_limit>
            <ci_upper_limit>0.371</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.566</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.140</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.312</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.002</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.139</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.655</ci_lower_limit>
            <ci_upper_limit>-0.197</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol (TC) at Week 12</title>
        <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol (TC) at Week 12</title>
          <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
          <population>mITT</population>
          <units>percent change in TC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="11.95"/>
                    <measurement group_id="O2" value="-1.7" spread="22.30"/>
                    <measurement group_id="O3" value="-1.8" spread="12.58"/>
                    <measurement group_id="O4" value="-3.6" spread="14.34"/>
                    <measurement group_id="O5" value="-1.7" spread="13.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.144</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.13</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.76</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.773</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.16</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.14</ci_lower_limit>
            <ci_upper_limit>4.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.963</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.79</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.73</ci_lower_limit>
            <ci_upper_limit>4.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.258</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.74</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.64</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Week 12</title>
        <description>LDL-C is known as the &quot;bad&quot; cholesterol, so a lower score (negative change) means improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Week 12</title>
          <description>LDL-C is known as the &quot;bad&quot; cholesterol, so a lower score (negative change) means improvement.</description>
          <population>mITT</population>
          <units>percent change in LDL-C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="17.34"/>
                    <measurement group_id="O2" value="2.8" spread="46.18"/>
                    <measurement group_id="O3" value="-0.1" spread="22.84"/>
                    <measurement group_id="O4" value="-2.4" spread="23.20"/>
                    <measurement group_id="O5" value="0.9" spread="20.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.228</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.50</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.74</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.894</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.51</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.36</ci_lower_limit>
            <ci_upper_limit>9.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.846</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.86</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.97</ci_lower_limit>
            <ci_upper_limit>7.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.409</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.77</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.82</ci_lower_limit>
            <ci_upper_limit>3.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HDL-C at Week 12</title>
        <description>HDL-C is known as the &quot;good&quot; cholesterol, so a higher score (positive change) means improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HDL-C at Week 12</title>
          <description>HDL-C is known as the &quot;good&quot; cholesterol, so a higher score (positive change) means improvement.</description>
          <population>mITT</population>
          <units>percent change in HCL-C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="11.48"/>
                    <measurement group_id="O2" value="1.1" spread="10.18"/>
                    <measurement group_id="O3" value="2.2" spread="11.59"/>
                    <measurement group_id="O4" value="1.1" spread="13.17"/>
                    <measurement group_id="O5" value="1.2" spread="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.576</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.59</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.83</ci_lower_limit>
            <ci_upper_limit>5.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.646</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.62</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.53</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.902</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.30</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.52</ci_lower_limit>
            <ci_upper_limit>4.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.478</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.27</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.35</ci_lower_limit>
            <ci_upper_limit>2.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Non-HDL-C at Week 12</title>
        <description>Non-HDL-C is the measure of &quot;bad&quot; cholesterol in the blood, including triglycerides and LDL-C, so a negative change means improvement. The equation for Non-HDL-C = LDL-C + (triglycerides/5).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Non-HDL-C at Week 12</title>
          <description>Non-HDL-C is the measure of &quot;bad&quot; cholesterol in the blood, including triglycerides and LDL-C, so a negative change means improvement. The equation for Non-HDL-C = LDL-C + (triglycerides/5).</description>
          <population>mITT</population>
          <units>Percent change in Non-HDL-C</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="14.89"/>
                    <measurement group_id="O2" value="-2.5" spread="31.68"/>
                    <measurement group_id="O3" value="-2.9" spread="16.68"/>
                    <measurement group_id="O4" value="-4.7" spread="19.10"/>
                    <measurement group_id="O5" value="-2.5" spread="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.072</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.22</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.57</ci_lower_limit>
            <ci_upper_limit>-0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.794</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.26</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.15</ci_lower_limit>
            <ci_upper_limit>5.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.946</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.75</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.45</ci_lower_limit>
            <ci_upper_limit>5.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.431</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.68</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.99</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides at Week 12</title>
        <description>Triglycerides are a type of fat found in the blood. The body uses them for energy. Some triglycerides are needed for good health. But high triglycerides might raise the risk of heart disease. Since Type 2 diabetics tend to have high triglycerides, a negative change means improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides at Week 12</title>
          <description>Triglycerides are a type of fat found in the blood. The body uses them for energy. Some triglycerides are needed for good health. But high triglycerides might raise the risk of heart disease. Since Type 2 diabetics tend to have high triglycerides, a negative change means improvement.</description>
          <population>mITT</population>
          <units>percent change in triglycerides</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="22.35"/>
                    <measurement group_id="O2" value="-1.9" spread="78.27"/>
                    <measurement group_id="O3" value="-5.8" spread="27.71"/>
                    <measurement group_id="O4" value="-7.0" spread="27.90"/>
                    <measurement group_id="O5" value="-3.0" spread="27.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.228</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.54</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.43</ci_lower_limit>
            <ci_upper_limit>3.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.951</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.62</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.70</ci_lower_limit>
            <ci_upper_limit>14.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.852</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.59</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.96</ci_lower_limit>
            <ci_upper_limit>11.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.608</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.45</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.13</ci_lower_limit>
            <ci_upper_limit>8.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Area-Under-the Curve 0-3 Hours (AUC0-3h) of Plasma Glucose (PG) in Response to the Mixed Meal Tolerance Test (MMTT) at Week 4</title>
        <description>The MMTT requires a participant to drink a &quot;mixed meal,&quot; such as Boost or Ensure, that contains protein, carbohydrates, and fat. The goal of the test is to find out how much insulin the pancreas makes in response to food by measuring the level of glucose in the blood. The lower the level of glucose in the blood during the first three hours after the test (AUC0-3h), the more insulin the body has made in response to the test. This would mean a negative change shows improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>mITT with a measurement at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Area-Under-the Curve 0-3 Hours (AUC0-3h) of Plasma Glucose (PG) in Response to the Mixed Meal Tolerance Test (MMTT) at Week 4</title>
          <description>The MMTT requires a participant to drink a &quot;mixed meal,&quot; such as Boost or Ensure, that contains protein, carbohydrates, and fat. The goal of the test is to find out how much insulin the pancreas makes in response to food by measuring the level of glucose in the blood. The lower the level of glucose in the blood during the first three hours after the test (AUC0-3h), the more insulin the body has made in response to the test. This would mean a negative change shows improvement.</description>
          <population>mITT with a measurement at baseline and Week 4</population>
          <units>(mg/dL)*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.32" spread="71.235"/>
                    <measurement group_id="O2" value="1.36" spread="67.661"/>
                    <measurement group_id="O3" value="-6.32" spread="83.597"/>
                    <measurement group_id="O4" value="-41.61" spread="73.971"/>
                    <measurement group_id="O5" value="-3.97" spread="87.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.728</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.289</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.932</ci_lower_limit>
            <ci_upper_limit>30.566</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.837</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.853</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.446</ci_lower_limit>
            <ci_upper_limit>22.914</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.791</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.747</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.352</ci_lower_limit>
            <ci_upper_limit>19.051</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.003</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-40.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.472</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.283</ci_lower_limit>
            <ci_upper_limit>-17.787</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in AUC0-3h of PG in Response to the MMTT at Week 12</title>
        <description>The MMTT requires a participant to drink a &quot;mixed meal,&quot; such as Boost or Ensure, that contains protein, carbohydrates, and fat. The goal of the test is to find out how much insulin the pancreas makes in response to food by measuring the level of glucose in the blood. The lower the level of glucose in the blood during the first three hours after the test (AUC0-3h), the more insulin the body has made in response to the test. This would mean a negative change shows improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>mITT with a measurement at baseline and Week 12</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AUC0-3h of PG in Response to the MMTT at Week 12</title>
          <description>The MMTT requires a participant to drink a &quot;mixed meal,&quot; such as Boost or Ensure, that contains protein, carbohydrates, and fat. The goal of the test is to find out how much insulin the pancreas makes in response to food by measuring the level of glucose in the blood. The lower the level of glucose in the blood during the first three hours after the test (AUC0-3h), the more insulin the body has made in response to the test. This would mean a negative change shows improvement.</description>
          <population>mITT with a measurement at baseline and Week 12</population>
          <units>(mg/dL)*hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.77" spread="96.472"/>
                    <measurement group_id="O2" value="13.81" spread="67.025"/>
                    <measurement group_id="O3" value="-5.51" spread="104.992"/>
                    <measurement group_id="O4" value="-53.40" spread="74.803"/>
                    <measurement group_id="O5" value="-24.16" spread="101.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.830</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>20.396</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.312</ci_lower_limit>
            <ci_upper_limit>38.087</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.235</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>24.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>20.335</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.354</ci_lower_limit>
            <ci_upper_limit>57.848</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.331</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>17.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.720</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.030</ci_lower_limit>
            <ci_upper_limit>46.529</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.091</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-29.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.393</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.254</ci_lower_limit>
            <ci_upper_limit>-0.775</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Maximum Concentration (Cmax) of PG in Response to MMTT at Week 4</title>
        <description>Cmax measures the highest amount of glucose in the blood, so a negative change means improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>mITT with a measurement at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Maximum Concentration (Cmax) of PG in Response to MMTT at Week 4</title>
          <description>Cmax measures the highest amount of glucose in the blood, so a negative change means improvement.</description>
          <population>mITT with a measurement at baseline and Week 4</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="41.260"/>
                    <measurement group_id="O2" value="-7.35" spread="39.645"/>
                    <measurement group_id="O3" value="-3.47" spread="54.258"/>
                    <measurement group_id="O4" value="-28.44" spread="45.327"/>
                    <measurement group_id="O5" value="-0.35" spread="41.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.873</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.280</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.835</ci_lower_limit>
            <ci_upper_limit>16.815</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.395</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-8.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.505</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.790</ci_lower_limit>
            <ci_upper_limit>7.604</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.761</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.306</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.247</ci_lower_limit>
            <ci_upper_limit>11.185</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-27.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.170</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.220</ci_lower_limit>
            <ci_upper_limit>-14.236</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cmax of PG in Response to MMTT at Week 12</title>
        <description>Cmax measures the highest amount of glucose in the blood, so a negative change means improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>mITT with a measurement at baseline and Week 12</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cmax of PG in Response to MMTT at Week 12</title>
          <description>Cmax measures the highest amount of glucose in the blood, so a negative change means improvement.</description>
          <population>mITT with a measurement at baseline and Week 12</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.93" spread="47.530"/>
                    <measurement group_id="O2" value="-1.10" spread="53.045"/>
                    <measurement group_id="O3" value="-4.43" spread="60.957"/>
                    <measurement group_id="O4" value="-28.29" spread="42.184"/>
                    <measurement group_id="O5" value="1.11" spread="58.731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.527</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.001</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.441</ci_lower_limit>
            <ci_upper_limit>12.221</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.532</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-7.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.532</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.927</ci_lower_limit>
            <ci_upper_limit>12.138</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.672</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.421</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.635</ci_lower_limit>
            <ci_upper_limit>12.807</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.002</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-31.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.229</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.482</ci_lower_limit>
            <ci_upper_limit>-14.676</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 2</title>
        <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>mITT with a measurement at baseline and Week 2</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 2</title>
          <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
          <population>mITT with a measurement at baseline and Week 2</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="25.98"/>
                    <measurement group_id="O2" value="-8.1" spread="25.24"/>
                    <measurement group_id="O3" value="0.0" spread="31.52"/>
                    <measurement group_id="O4" value="-16.2" spread="26.11"/>
                    <measurement group_id="O5" value="10.7" spread="32.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.298</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.90</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.90</ci_lower_limit>
            <ci_upper_limit>3.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.008</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-16.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.09</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.37</ci_lower_limit>
            <ci_upper_limit>-6.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.074</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-9.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.32</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.31</ci_lower_limit>
            <ci_upper_limit>-0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-27.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.32</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.96</ci_lower_limit>
            <ci_upper_limit>-18.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 4</title>
        <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>mITT with a measurement at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 4</title>
          <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
          <population>mITT with a measurement at baseline and Week 4</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="18.71"/>
                    <measurement group_id="O2" value="-12.7" spread="30.82"/>
                    <measurement group_id="O3" value="-5.9" spread="35.17"/>
                    <measurement group_id="O4" value="-11.1" spread="31.81"/>
                    <measurement group_id="O5" value="2.4" spread="32.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.840</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.96</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.04</ci_lower_limit>
            <ci_upper_limit>8.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.050</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.06</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.94</ci_lower_limit>
            <ci_upper_limit>-1.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.227</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.31</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.21</ci_lower_limit>
            <ci_upper_limit>2.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-13.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.27</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.83</ci_lower_limit>
            <ci_upper_limit>-4.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 8</title>
        <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>mITT with a measurement at baseline and Week 8</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 8</title>
          <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
          <population>mITT with a measurement at baseline and Week 8</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="27.57"/>
                    <measurement group_id="O2" value="-5.9" spread="27.90"/>
                    <measurement group_id="O3" value="-7.1" spread="37.51"/>
                    <measurement group_id="O4" value="-16.6" spread="32.96"/>
                    <measurement group_id="O5" value="-1.0" spread="31.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.642</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.55</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.77</ci_lower_limit>
            <ci_upper_limit>13.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.512</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.72</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.52</ci_lower_limit>
            <ci_upper_limit>6.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.486</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.81</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.66</ci_lower_limit>
            <ci_upper_limit>5.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.004</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-16.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.80</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.31</ci_lower_limit>
            <ci_upper_limit>-7.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</title>
        <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>mITT with a measurement at baseline and Week 12</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12</title>
          <description>Normal fasting plasma glucose -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline means improvement.</description>
          <population>mITT with a measurement at baseline and Week 12</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="25.67"/>
                    <measurement group_id="O2" value="-9.1" spread="34.89"/>
                    <measurement group_id="O3" value="-5.8" spread="35.27"/>
                    <measurement group_id="O4" value="-5.7" spread="46.29"/>
                    <measurement group_id="O5" value="8.1" spread="32.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.285</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-8.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.11</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.09</ci_lower_limit>
            <ci_upper_limit>4.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.020</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-18.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.94</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.73</ci_lower_limit>
            <ci_upper_limit>-5.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.067</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-13.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.60</ci_lower_limit>
            <ci_upper_limit>-1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference in change at week 12</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.012</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-17.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.88</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.76</ci_lower_limit>
            <ci_upper_limit>-6.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With HbA1c Less Than 7.0% at Week 12</title>
        <description>HbA1C less than 7% is the success goal for many Type 2 diabetics.</description>
        <time_frame>Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>DS-8500a 25mg</title>
            <description>One DS-8500a 25 mg tablet and placebo</description>
          </group>
          <group group_id="O2">
            <title>DS-8500a 50 mg</title>
            <description>Two DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O3">
            <title>DS-8500a 75 mg</title>
            <description>Three DS-8500a 25 mg tablets and placebo</description>
          </group>
          <group group_id="O4">
            <title>Sitagliptin 100 mg</title>
            <description>One sitagliptin 100 mg over-capsule and placebo</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo tablets and placebo capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With HbA1c Less Than 7.0% at Week 12</title>
          <description>HbA1C less than 7% is the success goal for many Type 2 diabetics.</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs), defined as adverse events (AEs) that first occurred or worsened in severity after initiation of double-blind treatment, were collected until the end of treatment (12 weeks), plus two weeks of follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DS-8500a 25mg</title>
          <description>One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose</description>
        </group>
        <group group_id="E2">
          <title>DS-8500a 50 mg</title>
          <description>Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose</description>
        </group>
        <group group_id="E3">
          <title>DS-8500a 75 mg</title>
          <description>Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose</description>
        </group>
        <group group_id="E4">
          <title>Sitagliptin 100 mg</title>
          <description>Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Three placebo tablets and one placebo capsule in a once-daily oral dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Accidental fire at one site changed the baseline number of participants for the modified intent to treat (mITT) set. Because of this, baseline data were included in the outcome measures, rather than in the baseline module.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Daiichi Sankyo Contact for Clinical Trial Information</name_or_title>
      <organization>Daiichi Sankyo</organization>
      <phone>+81-3-6225-1111(M-F 9-5 JST)</phone>
      <email>dsclinicaltrial@daiichisankyo.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

